The recent STELARA FDA approval marks a major milestone for families managing a challenging and chronic gastrointestinal condition. On April 15, 2026, the U.S. Food and Drug Administration (FDA) officially sanctioned STELARA® (ustekinumab) for the treatment of patients two years of age and older dealing with moderately to severely active Crohn’s disease (CD).
Nearly one million people live with Crohn’s disease in the United States, and up to 25% of those individuals are diagnosed during childhood. Pediatric Crohn’s disease is frequently more aggressive than adult-onset CD. It increases the risk of lifelong complications and severe growth impairment during a child’s most critical developmental years.
You can read more about the impact of the condition on children at the Crohn’s & Colitis Foundation. To read more about our ongoing commitment to immune therapies, visit our Immunology Research Updates page.
Learn More: STELARA® (ustekinumab) for Pediatric Crohn’s Disease: Johnson & Johnson Files for FDA Approval
Clinical Data from the Phase 3 UNITI-Jr Study
The STELARA FDA approval was heavily supported by clinical data gathered from the Phase 3 UNITI-Jr study (NCT04673357). This comprehensive 52-week, multicenter, open-label interventional study evaluated the safety, efficacy, and pharmacokinetics of STELARA. The trial was split into an 8-week induction phase and a 44-week maintenance phase.
The adverse reaction profile observed in these pediatric subjects was found to be similar to that reported in adult clinical trials for Crohn’s disease. Below are tables summarizing the clinical safety data regarding common adverse reactions (occurring in at least 10% of pediatric patients) observed during both phases of the trial:
Kura Oncology and Kyowa Kirin Announce Groundbreaking Kyowa Kirin Ziftomenib Frontline AML Data for EHA 2026 Congress
Kura Oncology and Kyowa Kirin announced updated frontline data for ziftomenib combined with 7+3 chemotherapy in newly diagnosed NPM1-m and KMT2A-r AML patients, demonstrating high […]
GSK and Spero Therapeutics Secure Historic Utebzi FDA Approval for Adults with Complicated Urinary Tract Infections
The historic Utebzi FDA approval introduces the first and only oral carbapenem antibiotic for adult patients suffering from complicated urinary tract infections (cUTIs), offering an […]
Novo Nordisk Cyber Attack: Threat Group Demands $25 Million Ransom Following Massive Data Breach
Following a rejected $25 million extortion attempt, a cybercriminal group claims to have stolen 1.3 terabytes of sensitive data in a sophisticated Novo Nordisk cyber […]
Adverse Reactions During the Induction Phase (8 Weeks)
| Adverse Reaction | Percentage of Pediatric Patients Affected |
| Upper respiratory tract infection | 13% |
Adverse Reactions During the Maintenance Phase (44 Weeks)
| Adverse Reaction | Percentage of Pediatric Patients Affected |
| Upper respiratory tract infection | 17% |
| COVID-19 | 17% |
| Headache | 10% |
